AC Immune, a Swiss clinical stage biopharmaceutical company pioneering in precision medicine for neurodegenerative diseases listed on the Nasdaq completed an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately USD 50.1 m. The offering was made pursuant to an effective shelf registration statement of AC Immune previously filed with the U.S. Securities and Exchange Commission. Jefferies and Leerink Partners acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.
Homburger advised Jefferies and Leerink Partners with respect to matters of Swiss law. The team consisted of partner Benjamin Leisinger (pictured) and associate Daniel Junginger (both Capital Markets).
Bär & Karrer acted as Swiss counsel to AC Immune. The team was led by Rolf Watter (Public Companies) and Shu Zhang (Capital Markets) and included Susanne Schreiber and Ariane Menzer (both Tax).